Page last updated: 2024-10-24

calmidazolium and Preleukemia

calmidazolium has been researched along with Preleukemia in 1 studies

calmidazolium: powerful inhibitor of or red blood cell Ca++-ATPase & Ca++ transport into inside-out red blood cell vesicles; RN refers to chloride; structure in first source; an antagonist of calmodulin
calmidazolium : An imidazolium ion that is imidazolium cation substituted by a bis(4-chlorophenyl)methyl group at position 1 and a 2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl group at position 3. It acts as an antagonist of calmodulin, a calcium binding messenger protein.

Preleukemia: Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Duraj, J1
Kovacikova, M1
Sedlak, J1
Koppel, J1
Sobel, A1
Chorvath, B1

Other Studies

1 other study available for calmidazolium and Preleukemia

ArticleYear
The protein kinase C inhibitor H7 blocks phosphorylation of stathmin during TPA-induced growth inhibition of human pre-B leukemia REH6 cells.
    Leukemia research, 1995, Volume: 19, Issue:7

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Burkitt Lymphoma; Calmodulin; Cell Cycle; Cell Divisi

1995